Valneva SE (VALN): Price and Financial Metrics


Valneva SE (VALN): $13.40

-0.14 (-1.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VALN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VALN Stock Price Chart Interactive Chart >

Price chart for VALN

VALN Price/Volume Stats

Current price $13.40 52-week high $40.70
Prev. close $13.54 52-week low $9.77
Day low $13.40 Volume 5,606
Day high $13.79 Avg. volume 5,300
50-day MA $13.97 Dividend yield N/A
200-day MA $18.13 Market Cap 926.92M

Valneva SE (VALN) Company Bio


Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.


VALN Latest News Stream


Event/Time News Detail
Loading, please wait...

VALN Latest Social Stream


Loading social stream, please wait...

View Full VALN Social Stream

Latest VALN News From Around the Web

Below are the latest news stories about VALNEVA SE that investors may wish to consider to help them evaluate VALN as an investment opportunity.

10 Best Healthcare Stocks For the Long Term

In this article, we will take a look at the 10 best healthcare stocks for the long term. You can skip this part and go to 5 Best Healthcare Stocks For the Long Term. The healthcare sector is one of those rare, evergreen areas of the industry that refuse to waver even when the entire […]

Yahoo | January 21, 2023

VALNEVA - Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023

VALNEVA Declaration of shares and voting rightsStatus on December 31, 2022 (corrected data) and January 4, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: January 19, 2023 Erratum: status on December 31, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights

Yahoo | January 19, 2023

Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why

Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

Yahoo | January 16, 2023

VALNEVA - Declaration of shares and voting rights: December 31, 2022

VALNEVA

GlobeNewswire | January 5, 2023

What Makes Valneva SE Sponsored ADR (VALN) a New Buy Stock

Valneva SE Sponsored ADR (VALN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | January 3, 2023

Read More 'VALN' Stories Here

VALN Price Returns

1-mo 5.35%
3-mo -4.11%
6-mo -33.71%
1-year -60.67%
3-year N/A
5-year N/A
YTD 5.35%
2022 -77.09%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6558 seconds.